Vaccine and Immunization

5-Methylcytidine 5′-triphosphate trisodium (5-Methyl-CTP trisodium) is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research.

5-Methylcytidine 5′-triphosphate (5-Methyl-CTP) is a modified ribonucleoside 5′-triphosphate. When incorporated into mRNA, 5-Methylcytidine 5′-triphosphate enhances the translation efficiency and stability of the mRNA, and reduces the innate immune response. 5-Methylcytidine 5′-triphosphate can be used in studies related to gene replacement and vaccination applications.

L2H2-6OTD diformic is a G-quadruplex (G-quadruplex, G4) ligand and telomerase (telomerase) inhibitor, with an IC₅₀ of 15 nM against human telomerase. L2H2-6OTD diformic induces the formation of antiparallel G-quadruplex structures in long telomeric DNA. L2H2-6OTD diformic stabilizes the G4 structure of GD3 and enhances the immunological activity of CpG ODN. L2H2-6OTD diformic is applicable to research related to the development of G4-CpG immune adjuvants.

Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection.

TLR7 agonist 20 hydrochloride is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 0.22 μM. TLR7 agonist 20 hydrochloride, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 hydrochloride can be used in studies related to non-inflammatory potent vaccine adjuvants.

ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD).

Globotriaosylceramide (non-hydroxy) (porcine RBC) is a glycosphingolipid found in the cell membranes of mammals. Globotriaosylceramide (non-hydroxy) (porcine RBC) is the core pathogenic molecule of Fabry disease, and its level can be downregulated by supplementing α-galactosidase A. Globotriaosylceramide (non-hydroxy) (porcine RBC) amplifies B-cell receptor signals by regulating the localization of co-receptor CD19, and can be used as a vaccine adjuvant, capable of guiding the generation of broad-spectrum and cross-protective antibody responses. Globotriaosylceramide (non-hydroxy) (porcine RBC) promotes wound healing and reduces scar formation by regulating fibroblast heterogeneity.

OVA mRNA (N1-Me-Pseudo UTP) is an mRNA encoding chicken ovalbumin. The substitution with N1-Me-Pseudo UTP (m1Ψ) improves protein expression and reduces innate immune response. OVA mRNA binds to the STING-activating polymer PD18 and is encapsulated in optimized lipid nanoparticles to construct an mRNA vaccine platform (PD18 LNP). This platform not only enhances the lymphatic delivery efficiency and protein expression of mRNA, but also potently adjuvates immune responses via activating the STING pathway.

5-Methylcytidine 5′-triphosphate-d₃ trisodium (5-Methyl-CTP-d₃ trisodium) is the deuterated-labeled 5-Methylcytidine 5′-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate trisodium is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research.

5-Methylcytidine 5′-triphosphate-d₈ trisodium (5-Methyl-CTP-d₈ trisodium) is the deuterated-labeled 5-Methylcytidine 5′-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate trisodium is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research.

503O8,12 is an ionizable cationic lipidoid that enables mRNA delivery to the spleen and lungs in mice when formulated into lipid nanoparticles with neutral helper lipid DOPE[1].

GAP214 is a monosaccharide lipid A analogue and TLR4/MD-2 complex modulator.GAP214 binds to the TLR4/MD-2 complex via hydrophobic interactions, salt bridges, and hydrogen bonds, induces dimerization of the complex to initiate intracellular signaling cascades.GAP214 functions as an immunostimulant and vaccine adjuvant, enhances antigen-specific IgG antibody production in a mouse model.

5-Methylcytidine 5′-triphosphate-¹⁵N₂, ¹³C trisodium (5-Methyl-CTP-¹⁵N₂, ¹³C trisodium) is the ¹³C, ¹⁵N-labeled 5-Methylcytidine 5′-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate trisodium is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research.